Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium tuberculosis | 28 | 2025 | 287 | 4.260 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 14 | 2023 | 40 | 3.260 |
Why?
|
| Antitubercular Agents | 19 | 2023 | 106 | 2.580 |
Why?
|
| Tuberculosis | 11 | 2025 | 148 | 2.000 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 13 | 2023 | 63 | 1.420 |
Why?
|
| Microbial Sensitivity Tests | 16 | 2023 | 271 | 1.300 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 8 | 2023 | 12 | 1.110 |
Why?
|
| Latent Tuberculosis | 4 | 2024 | 10 | 0.860 |
Why?
|
| Tuberculosis, Pulmonary | 6 | 2024 | 108 | 0.740 |
Why?
|
| Mutation | 10 | 2020 | 1292 | 0.620 |
Why?
|
| Molecular Diagnostic Techniques | 7 | 2025 | 33 | 0.610 |
Why?
|
| Bacterial Proteins | 9 | 2023 | 372 | 0.580 |
Why?
|
| Population Dynamics | 1 | 2016 | 17 | 0.560 |
Why?
|
| Fluoroquinolones | 5 | 2023 | 24 | 0.530 |
Why?
|
| Drug Resistance, Bacterial | 4 | 2017 | 72 | 0.520 |
Why?
|
| Sequence Analysis, DNA | 8 | 2019 | 237 | 0.460 |
Why?
|
| Isoniazid | 6 | 2023 | 37 | 0.400 |
Why?
|
| Sensitivity and Specificity | 7 | 2025 | 858 | 0.380 |
Why?
|
| DNA, Bacterial | 6 | 2019 | 187 | 0.370 |
Why?
|
| Humans | 36 | 2025 | 49929 | 0.320 |
Why?
|
| Air Pollution | 2 | 2019 | 44 | 0.300 |
Why?
|
| Air Pollutants | 2 | 2019 | 64 | 0.300 |
Why?
|
| India | 6 | 2018 | 52 | 0.300 |
Why?
|
| Adult | 15 | 2025 | 13356 | 0.280 |
Why?
|
| Middle Aged | 13 | 2025 | 12293 | 0.260 |
Why?
|
| Sputum | 5 | 2016 | 65 | 0.260 |
Why?
|
| Young Adult | 10 | 2025 | 4031 | 0.260 |
Why?
|
| Moldova | 7 | 2024 | 11 | 0.260 |
Why?
|
| California | 3 | 2019 | 87 | 0.240 |
Why?
|
| Prospective Studies | 8 | 2025 | 2345 | 0.220 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2022 | 20 | 0.210 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2019 | 168 | 0.210 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2022 | 2 | 0.210 |
Why?
|
| Lung Diseases | 1 | 2023 | 96 | 0.200 |
Why?
|
| Directly Observed Therapy | 2 | 2020 | 7 | 0.200 |
Why?
|
| Male | 14 | 2025 | 25454 | 0.200 |
Why?
|
| Disease Progression | 1 | 2024 | 820 | 0.190 |
Why?
|
| Aged | 9 | 2025 | 9449 | 0.190 |
Why?
|
| South Africa | 6 | 2018 | 22 | 0.190 |
Why?
|
| Pneumonia | 1 | 2022 | 117 | 0.190 |
Why?
|
| Female | 14 | 2025 | 26576 | 0.190 |
Why?
|
| Laboratories | 1 | 2020 | 20 | 0.180 |
Why?
|
| Residence Characteristics | 2 | 2019 | 151 | 0.180 |
Why?
|
| Trees | 1 | 2019 | 18 | 0.170 |
Why?
|
| Urban Health Services | 1 | 2019 | 21 | 0.170 |
Why?
|
| Bacteriological Techniques | 2 | 2017 | 42 | 0.170 |
Why?
|
| Health Care Costs | 2 | 2018 | 168 | 0.170 |
Why?
|
| Transcriptome | 1 | 2021 | 312 | 0.160 |
Why?
|
| DNA Gyrase | 2 | 2015 | 4 | 0.160 |
Why?
|
| Catalase | 2 | 2015 | 68 | 0.160 |
Why?
|
| HIV Infections | 1 | 2022 | 355 | 0.150 |
Why?
|
| Adolescent | 8 | 2025 | 6417 | 0.150 |
Why?
|
| Kanamycin | 4 | 2023 | 6 | 0.150 |
Why?
|
| Vehicle Emissions | 1 | 2017 | 10 | 0.150 |
Why?
|
| ROC Curve | 1 | 2017 | 225 | 0.140 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 20 | 0.130 |
Why?
|
| Specimen Handling | 1 | 2016 | 54 | 0.130 |
Why?
|
| Risk Factors | 3 | 2024 | 3605 | 0.130 |
Why?
|
| Cohort Studies | 2 | 2017 | 1403 | 0.130 |
Why?
|
| Child | 7 | 2025 | 6849 | 0.130 |
Why?
|
| Rifampin | 3 | 2023 | 62 | 0.120 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 584 | 0.120 |
Why?
|
| Capreomycin | 3 | 2023 | 4 | 0.110 |
Why?
|
| Logistic Models | 1 | 2016 | 896 | 0.110 |
Why?
|
| Genotype | 4 | 2017 | 539 | 0.110 |
Why?
|
| Point Mutation | 1 | 2013 | 65 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1354 | 0.110 |
Why?
|
| Prevalence | 1 | 2016 | 956 | 0.110 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 3138 | 0.110 |
Why?
|
| Interferon-gamma | 2 | 2024 | 176 | 0.110 |
Why?
|
| Research Design | 1 | 2014 | 344 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 4 | 2016 | 467 | 0.100 |
Why?
|
| Lung | 1 | 2016 | 501 | 0.100 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 1576 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2017 | 1255 | 0.090 |
Why?
|
| Predictive Value of Tests | 3 | 2022 | 907 | 0.090 |
Why?
|
| Lyme Disease | 1 | 2011 | 32 | 0.090 |
Why?
|
| Oxidoreductases | 3 | 2015 | 59 | 0.090 |
Why?
|
| Environment | 1 | 2011 | 83 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 2 | 2015 | 742 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2019 | 483 | 0.080 |
Why?
|
| Antigens, Bacterial | 2 | 2024 | 54 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 1182 | 0.080 |
Why?
|
| Amikacin | 2 | 2023 | 19 | 0.080 |
Why?
|
| Phenotype | 3 | 2015 | 728 | 0.070 |
Why?
|
| Incidence | 2 | 2024 | 986 | 0.070 |
Why?
|
| Time Factors | 3 | 2019 | 2891 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 2 | 2019 | 269 | 0.060 |
Why?
|
| Pakistan | 1 | 2025 | 19 | 0.060 |
Why?
|
| Contact Tracing | 1 | 2024 | 9 | 0.060 |
Why?
|
| Philippines | 2 | 2015 | 9 | 0.060 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2024 | 25 | 0.060 |
Why?
|
| Tuberculin Test | 1 | 2023 | 9 | 0.060 |
Why?
|
| Interferon-gamma Release Tests | 1 | 2023 | 8 | 0.060 |
Why?
|
| Peptides | 1 | 2024 | 220 | 0.050 |
Why?
|
| Mitochondrial Dynamics | 1 | 2022 | 18 | 0.050 |
Why?
|
| Kenya | 1 | 2022 | 10 | 0.050 |
Why?
|
| Pathology, Molecular | 1 | 2022 | 22 | 0.050 |
Why?
|
| Proteome | 1 | 2024 | 153 | 0.050 |
Why?
|
| England | 1 | 2021 | 45 | 0.050 |
Why?
|
| Tissue Array Analysis | 1 | 2021 | 45 | 0.050 |
Why?
|
| State Medicine | 1 | 2021 | 14 | 0.050 |
Why?
|
| San Francisco | 1 | 2020 | 12 | 0.040 |
Why?
|
| United States | 2 | 2022 | 4883 | 0.040 |
Why?
|
| New York City | 1 | 2020 | 26 | 0.040 |
Why?
|
| Ofloxacin | 1 | 2019 | 7 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 693 | 0.040 |
Why?
|
| Algorithms | 1 | 2022 | 613 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 92 | 0.040 |
Why?
|
| Video Recording | 1 | 2018 | 79 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1129 | 0.040 |
Why?
|
| Pyrazinamide | 1 | 2017 | 7 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2018 | 130 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2016 | 3879 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 176 | 0.030 |
Why?
|
| Kanamycin Resistance | 1 | 2016 | 1 | 0.030 |
Why?
|
| Molecular Typing | 1 | 2016 | 10 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 314 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 1028 | 0.030 |
Why?
|
| Genes, Bacterial | 1 | 2016 | 64 | 0.030 |
Why?
|
| Bacterial Load | 1 | 2016 | 12 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 404 | 0.030 |
Why?
|
| Reference Standards | 1 | 2016 | 52 | 0.030 |
Why?
|
| Calibration | 1 | 2016 | 57 | 0.030 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2016 | 55 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 2017 | 201 | 0.030 |
Why?
|
| Pharmaceutical Preparations | 1 | 2016 | 76 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 670 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2015 | 44 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2015 | 96 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2015 | 38 | 0.030 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2014 | 14 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2014 | 109 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2014 | 70 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2016 | 702 | 0.030 |
Why?
|
| Base Sequence | 1 | 2014 | 657 | 0.030 |
Why?
|
| Acetyltransferases | 1 | 2012 | 19 | 0.030 |
Why?
|
| Methyltransferases | 1 | 2012 | 29 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2022 | 5178 | 0.020 |
Why?
|
| Maryland | 1 | 2011 | 32 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 719 | 0.020 |
Why?
|